These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34353749)

  • 21. High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.
    Morgan TM; Rossi PJ; Cutrell PK; Zhang C; Press RH; Rahnema S; Sanda M; Pattaras J; Cimmino C; Hershatter B; Jani AB; Patel PR
    Brachytherapy; 2019; 18(6):793-799. PubMed ID: 31337543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
    Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution.
    Ong WL; Matheson B; Millar J
    Brachytherapy; 2017; 16(2):313-322. PubMed ID: 28017293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal resolution of urinary morbidity following prostate brachytherapy.
    Merrick GS; Butler WM; Lief JH; Dorsey AT
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.
    Yu YD; Kang MH; Choi CI; Shin HS; Oh JJ; Park DS
    World J Urol; 2016 Sep; 34(9):1269-74. PubMed ID: 26868648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer.
    Tsang YM; Vignarajah D; Mcwilliam A; Tharmalingam H; Lowe G; Choudhury A; Hoskin P
    Br J Radiol; 2020 Feb; 93(1106):20190760. PubMed ID: 31778319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?
    Keyes M; Schellenberg D; Moravan V; McKenzie M; Agranovich A; Pickles T; Wu J; Liu M; Bucci J; Morris WJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):825-34. PubMed ID: 16458775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
    Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
    Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.
    Crook J; Toi A; McLean M; Pond G
    Brachytherapy; 2002; 1(3):131-7. PubMed ID: 15090275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.
    Winoker JS; Say RK; Mehrazin R; Stock RG; Stone NN
    Brachytherapy; 2019; 18(3):332-337. PubMed ID: 30890317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
    Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
    Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: a matched case-control study.
    Earley JJ; Abdelbaky AM; Cunningham MJ; Chadwick E; Langley SE; Laing RW
    Radiother Oncol; 2012 Aug; 104(2):187-91. PubMed ID: 22841018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
    Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
    Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.